Wednesday, April 6th, 2022
2 pm EDT, 11 am PDT, 7 pm GMT
Throughout the preclinical drug development process, high-quality liquid chromatography-mass spectrometry (LC-MS) data fosters actionable insights. The pioneers of accelerated drug development have adapted MS-based strategies for early identification and monitoring of drug candidate’s presumptive Critical Quality Attributes (pCQA). Accurate compound and process characterization enables faster development, increasing probability of success in human clinical trials.
Key Learning Objectives:
Who Should Attend:
Lieza Danan Leon, Ph.D., Co-Founder and CEO, LiVeritas BioSciences, Inc, South San Francisco, CA , USA
Na Pi Parra, Ph.D., Co-Founder and EVP of Marketing and Project Management, LiVeritas BioSciences, Inc, South San Francisco, CA , USA
For Research Use Only. Not for use in clinical diagnostic procedures.